恢复PML肿瘤抑制作用以对抗癌症。 - Suppr

Suppr

超能文献

Restoring PML tumor suppression to combat cancer.

作者信息

Wolyniec Kamil, Chan Ai-Leen, Haupt Sue, Haupt Ygal

出版信息

Cell Cycle. 2012 Oct 15;11(20):3705-6. doi: 10.4161/cc.22043. Epub 2012 Sep 14.

DOI:10.4161/cc.22043

PMID:22983003

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3495802/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0579/3495802/24204f4b5ff2/cc-11-3705-g1.jpg

相似文献

Restoring PML tumor suppression to combat cancer.

Cell Cycle. 2012 Oct 15;11(20):3705-6. doi: 10.4161/cc.22043. Epub 2012 Sep 14.

Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.

Cell Cycle. 2010 Aug 1;9(15):3085-99. doi: 10.4161/cc.9.15.12521. Epub 2010 Aug 26.

PML promotes senescence via JAK/STAT signaling.

Cell Cycle. 2010 Aug 1;9(15):2931. doi: 10.4161/cc.9.15.12697.

Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.

J Neurochem. 2008 Jan;104(1):89-99. doi: 10.1111/j.1471-4159.2007.05019.x. Epub 2007 Nov 6.

The role of PML ubiquitination in human malignancies.

J Biomed Sci. 2012 Aug 30;19(1):81. doi: 10.1186/1423-0127-19-81.

SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.

Cancer Res. 2014 Dec 1;74(23):6935-46. doi: 10.1158/0008-5472.CAN-14-1330. Epub 2014 Oct 7.

CK2 and PML: regulating the regulator.

Cell. 2006 Jul 28;126(2):244-5. doi: 10.1016/j.cell.2006.07.004.

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

Gastroenterology. 2012 Mar;142(3):572-81. doi: 10.1053/j.gastro.2011.11.041. Epub 2011 Dec 9.

Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.

Exp Cell Res. 2007 Aug 1;313(13):2753-65. doi: 10.1016/j.yexcr.2007.03.032. Epub 2007 Apr 1.

Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies.

Int J Biol Sci. 2009 May 22;5(4):366-76. doi: 10.7150/ijbs.5.366.

引用本文的文献

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Oncogene. 2016 Dec 1;35(48):6235-6245. doi: 10.1038/onc.2016.159. Epub 2016 Sep 19.

New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.

Front Oncol. 2013 May 17;3:124. doi: 10.3389/fonc.2013.00124. eCollection 2013.

Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Cell Cycle. 2013 Jun 1;12(11):1722-31. doi: 10.4161/cc.24805. Epub 2013 May 8.

本文引用的文献

E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.

Blood. 2012 Jul 26;120(4):822-32. doi: 10.1182/blood-2011-10-387647. Epub 2012 Jun 11.

Role of the promyelocytic leukaemia protein in cell death regulation.

Cell Death Dis. 2012 Jan 12;3(1):e247. doi: 10.1038/cddis.2011.122.

Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library.

Chem Biol. 2011 Dec 23;18(12):1562-70. doi: 10.1016/j.chembiol.2011.09.013.

Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Cancer Cell. 2010 Sep 14;18(3):258-67. doi: 10.1016/j.ccr.2010.08.008.

p53--a Jack of all trades but master of none.

Nat Rev Cancer. 2009 Nov;9(11):821-9. doi: 10.1038/nrc2728. Epub 2009 Sep 24.

E6AP promotes the degradation of the PML tumor suppressor.

Cell Death Differ. 2009 Aug;16(8):1156-66. doi: 10.1038/cdd.2009.31. Epub 2009 Mar 27.

PML targeting eradicates quiescent leukaemia-initiating cells.

Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11.

Marked for death.

Nat Cell Biol. 2008 May;10(5):507-9. doi: 10.1038/ncb0508-507.

Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.

Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16. doi: 10.1038/nrm2277.

A CK2-dependent mechanism for degradation of the PML tumor suppressor.

Cell. 2006 Jul 28;126(2):269-83. doi: 10.1016/j.cell.2006.05.041.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Restoring PML tumor suppression to combat cancer.

Cell Cycle. 2012 Oct 15;11(20):3705-6. doi: 10.4161/cc.22043. Epub 2012 Sep 14.

Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.

Cell Cycle. 2010 Aug 1;9(15):3085-99. doi: 10.4161/cc.9.15.12521. Epub 2010 Aug 26.

PML promotes senescence via JAK/STAT signaling.

Cell Cycle. 2010 Aug 1;9(15):2931. doi: 10.4161/cc.9.15.12697.

Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.

J Neurochem. 2008 Jan;104(1):89-99. doi: 10.1111/j.1471-4159.2007.05019.x. Epub 2007 Nov 6.

The role of PML ubiquitination in human malignancies.

J Biomed Sci. 2012 Aug 30;19(1):81. doi: 10.1186/1423-0127-19-81.

SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.

Cancer Res. 2014 Dec 1;74(23):6935-46. doi: 10.1158/0008-5472.CAN-14-1330. Epub 2014 Oct 7.

CK2 and PML: regulating the regulator.

Cell. 2006 Jul 28;126(2):244-5. doi: 10.1016/j.cell.2006.07.004.

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

Gastroenterology. 2012 Mar;142(3):572-81. doi: 10.1053/j.gastro.2011.11.041. Epub 2011 Dec 9.

Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.

Exp Cell Res. 2007 Aug 1;313(13):2753-65. doi: 10.1016/j.yexcr.2007.03.032. Epub 2007 Apr 1.

Targeting promyelocytic leukemia protein: a means to regulating PML nuclear bodies.

Int J Biol Sci. 2009 May 22;5(4):366-76. doi: 10.7150/ijbs.5.366.

引用本文的文献

Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP.

Oncogene. 2016 Dec 1;35(48):6235-6245. doi: 10.1038/onc.2016.159. Epub 2016 Sep 19.

New Strategies to Direct Therapeutic Targeting of PML to Treat Cancers.

Front Oncol. 2013 May 17;3:124. doi: 10.3389/fonc.2013.00124. eCollection 2013.

Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Cell Cycle. 2013 Jun 1;12(11):1722-31. doi: 10.4161/cc.24805. Epub 2013 May 8.

本文引用的文献

E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.

Blood. 2012 Jul 26;120(4):822-32. doi: 10.1182/blood-2011-10-387647. Epub 2012 Jun 11.

Role of the promyelocytic leukaemia protein in cell death regulation.

Cell Death Dis. 2012 Jan 12;3(1):e247. doi: 10.1038/cddis.2011.122.

Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library.

Chem Biol. 2011 Dec 23;18(12):1562-70. doi: 10.1016/j.chembiol.2011.09.013.

Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Cancer Cell. 2010 Sep 14;18(3):258-67. doi: 10.1016/j.ccr.2010.08.008.

p53--a Jack of all trades but master of none.

Nat Rev Cancer. 2009 Nov;9(11):821-9. doi: 10.1038/nrc2728. Epub 2009 Sep 24.

E6AP promotes the degradation of the PML tumor suppressor.

Cell Death Differ. 2009 Aug;16(8):1156-66. doi: 10.1038/cdd.2009.31. Epub 2009 Mar 27.

PML targeting eradicates quiescent leukaemia-initiating cells.

Nature. 2008 Jun 19;453(7198):1072-8. doi: 10.1038/nature07016. Epub 2008 May 11.

Marked for death.

Nat Cell Biol. 2008 May;10(5):507-9. doi: 10.1038/ncb0508-507.

Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.

Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16. doi: 10.1038/nrm2277.

A CK2-dependent mechanism for degradation of the PML tumor suppressor.

Cell. 2006 Jul 28;126(2):269-83. doi: 10.1016/j.cell.2006.05.041.